Analysis of the early benefit assessment in the indication NSCLC in Germany – which factors affect the price?
For further discussion about the analysis of the early benefit assessment in the indication NSCLC in Germany and the factors affecting the price, we would like to invite you to our chat at the Virtual ISPOR Europe 2020 conference on Monday, 16 November 2020, 4.30 pm – 6.00 pm.
Since the introduction of the German Act on the Reform of the Market for Medicinal Products (AMNOG) law in 2011, a total of 35 early benefit assessments for 15 pharmaceutical products were assessed by the Federal Joint Committee (G-BA) in the indication NSCLC until June 2020. The net annual therapy costs (ATC) of NSCLC products after price negotiation fluctuated between 14.405 € and 83.980 €. However, the costs for pharmaceutical products for the indication NSCLC remained relatively constant in the last years. Furthermore, the net rebates after price negotiation over the years varied between 12.84 % and 71.37 %.
A correlation was found between the added benefit category and the negotiated price rebate. Lower rebates were achieved for NSCLC products that were granted an added benefit and the negotiated rebates decreased with higher added benefit categories. Conversely, a lower added benefit category was associated with a higher negotiated rebate. Hence, the added benefit category has a great impact on the ATC of NSCLC pharmaceutical products in Germany. Additionally, lower negotiated rebates were achieved for drugs targeting the ALK/ROS1 mutation compared to drugs with other mechanism of actions. Another factor of value affecting the reimbursed price were the costs of the appropriate comparative therapy (ACT). Lower costs of the ACT combined with a lower added benefit category were associated with lower ATC. Overall, the outcome of the benefit assessment in the indication NSCLC in Germany depends on several factors that should be critically evaluated for a successful market access.